Closing the Gap in Care in Seronegative Inflammatory Arthritis (Metrix II)

April 5, 2017 updated by: Pope Research Corporation

Closing the Gap in Care in Seronegative Inflammatory Arthritis: From Identification to Implementation of Treating to Target: A Randomized Trial of Feedback, Education, and Behavioural Change

Rheumatologists treating patients with seronegative arthritis will be randomized to treat their patients to a target or to treat their patients under their usual standard of care. All physicians will perform an initial chart audit. Following the initial chart audit, all physicians in the treat-to-target group will receive accredited educational training. Six months after the initial chart audit, all physicians will perform a repeat audit to see if patients are assessed more systematically and treated to a target of low disease state.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Brampton, Ontario, Canada
        • Dr. Vandana Ahluwalia
      • Burlington, Ontario, Canada, L7L 0B7
        • Dr. Sanjay Dixit
      • Hamilton, Ontario, Canada, L8N 1Y2
        • Dr Pauline Boulos
      • London, Ontario, Canada, N6B 2E8
        • Dr. Nikhil Chopra
      • Mississauga, Ontario, Canada, L5M 2V8
        • Credit Valley Rheumatology
      • Mississauga, Ontario, Canada, L5B 2P7
        • Dr Angela Montgomery
      • Peterborough, Ontario, Canada, K9J 7B3
        • The Medical Centre
      • Toronto, Ontario, Canada, M4N 3M5
        • SunnyBrook Health Sciences Centre
      • Toronto, Ontario, Canada, M9C 5N2
        • Dr. Arthur Karasik

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Canadian Rheumatologist

Exclusion Criteria:

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: No education or feedback
Rheumatologists randomized to this treatment arm receive no additional education or feedback about their systematic assessments of patients
Experimental: Education and Feedback
Rheumatologists randomized to receive education and feedback participate in six web conferences designed to improve their systematic assessments of their patients, and are given feedback about their performances
Behavioral: Education and Feedback
Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Improvement of Systematic Assessments
Time Frame: November 2012 - November 2013
Physicians in the Education and Feedback arm are assessed via a needs assessment to identify the care gaps for their patients with inflammatory arthritis. After the education and feedback, they complete a second chart audit and their improvements in assessments is recorded.
November 2012 - November 2013

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pope Research Corporation

Collaborators

Abbott
Academic Medical Organization of Southwestern Ontario

Investigators

  • Principal Investigator: Janet E Pope, MD, MPH, FRCPC, Pope Research Corp., St. Joseph's Health Care, Western University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2012

Primary Completion (Actual)

November 1, 2016

Study Completion (Actual)

November 1, 2016

Study Registration Dates

First Submitted

November 6, 2012

First Submitted That Met QC Criteria

December 13, 2012

First Posted (Estimate)

December 17, 2012

Study Record Updates

Last Update Posted (Actual)

April 7, 2017

Last Update Submitted That Met QC Criteria

April 5, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Metrix II

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on SpA

Clinical Trials on Education and Feedback

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe